Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
As it becomes evident that the microbiome exerts an influence on the human immune system, scientists have begun to ponder therapies that might act on intestinal microbes to reduce harmful inflammation. Roxanne Khamsi reports.
Recent news of raids on research budgets illustrates how precarious government funding of scientific research has become. In an era of unprecedented momentum in the development of technologies and therapies for studying and treating disease, opportunities for new discoveries must not be lost due to shortsighted budgetary concerns.
Recent clinical data suggest that combination immunotherapy may be the wave of the future. To capitalize on these exciting findings, the scientific, logistical, proprietary and financial hurdles to the clinical testing of combination therapy must be addressed.